TW201311896A - 製備病毒抗原及疫苗之方法 - Google Patents
製備病毒抗原及疫苗之方法 Download PDFInfo
- Publication number
- TW201311896A TW201311896A TW101126141A TW101126141A TW201311896A TW 201311896 A TW201311896 A TW 201311896A TW 101126141 A TW101126141 A TW 101126141A TW 101126141 A TW101126141 A TW 101126141A TW 201311896 A TW201311896 A TW 201311896A
- Authority
- TW
- Taiwan
- Prior art keywords
- virus
- enveloped
- viral
- carried out
- chromatography
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 164
- 230000003612 virological effect Effects 0.000 title claims abstract description 92
- 239000000427 antigen Substances 0.000 title claims abstract description 83
- 102000036639 antigens Human genes 0.000 title claims abstract description 83
- 108091007433 antigens Proteins 0.000 title claims abstract description 83
- 229960005486 vaccine Drugs 0.000 title claims abstract description 41
- 230000008569 process Effects 0.000 title description 27
- 241000700605 Viruses Species 0.000 claims abstract description 163
- 239000007788 liquid Substances 0.000 claims abstract description 52
- 239000012530 fluid Substances 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 98
- 239000003599 detergent Substances 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 53
- 238000009295 crossflow filtration Methods 0.000 claims description 31
- 125000002091 cationic group Chemical group 0.000 claims description 27
- 235000013601 eggs Nutrition 0.000 claims description 26
- 239000012459 cleaning agent Substances 0.000 claims description 24
- 230000009849 deactivation Effects 0.000 claims description 23
- 238000005199 ultracentrifugation Methods 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 238000005119 centrifugation Methods 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 17
- 238000004587 chromatography analysis Methods 0.000 claims description 15
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 13
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 12
- 241000712461 unidentified influenza virus Species 0.000 claims description 12
- 238000001042 affinity chromatography Methods 0.000 claims description 10
- 238000011210 chromatographic step Methods 0.000 claims description 10
- 244000309457 enveloped RNA virus Species 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 9
- 108010067390 Viral Proteins Proteins 0.000 claims description 8
- 238000004255 ion exchange chromatography Methods 0.000 claims description 7
- 101710163270 Nuclease Proteins 0.000 claims description 6
- 238000011118 depth filtration Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 238000002298 density-gradient ultracentrifugation Methods 0.000 claims description 5
- 229960003971 influenza vaccine Drugs 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 210000003097 mucus Anatomy 0.000 claims description 5
- 210000004102 animal cell Anatomy 0.000 claims description 4
- 102000038379 digestive enzymes Human genes 0.000 claims description 4
- 108091007734 digestive enzymes Proteins 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 230000002440 hepatic effect Effects 0.000 claims description 3
- 241000701447 unidentified baculovirus Species 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 241000713112 Orthobunyavirus Species 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 241001500351 Influenzavirus A Species 0.000 claims 1
- 241001500350 Influenzavirus B Species 0.000 claims 1
- 241001500343 Influenzavirus C Species 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000003306 harvesting Methods 0.000 abstract description 11
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 description 47
- 101710154606 Hemagglutinin Proteins 0.000 description 45
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 45
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 45
- 101710176177 Protein A56 Proteins 0.000 description 45
- 239000000185 hemagglutinin Substances 0.000 description 45
- 238000011084 recovery Methods 0.000 description 29
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 27
- 238000005063 solubilization Methods 0.000 description 24
- 230000007928 solubilization Effects 0.000 description 24
- 108010006232 Neuraminidase Proteins 0.000 description 22
- 102000005348 Neuraminidase Human genes 0.000 description 22
- 229920001429 chelating resin Polymers 0.000 description 22
- 239000000047 product Substances 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 239000002245 particle Substances 0.000 description 17
- 238000005352 clarification Methods 0.000 description 16
- 239000012535 impurity Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000011282 treatment Methods 0.000 description 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 13
- 229920000053 polysorbate 80 Polymers 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000009286 beneficial effect Effects 0.000 description 12
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 12
- -1 alkyltrimethylammonium salt Chemical class 0.000 description 11
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 11
- 238000011027 product recovery Methods 0.000 description 11
- 230000000644 propagated effect Effects 0.000 description 11
- 229960000380 propiolactone Drugs 0.000 description 11
- 238000000108 ultra-filtration Methods 0.000 description 11
- 239000000356 contaminant Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 206010022000 influenza Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 229940124873 Influenza virus vaccine Drugs 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229960004854 viral vaccine Drugs 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 229920000151 polyglycol Polymers 0.000 description 4
- 239000010695 polyglycol Substances 0.000 description 4
- 230000001932 seasonal effect Effects 0.000 description 4
- 229940031626 subunit vaccine Drugs 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000037262 Hepatitis delta Diseases 0.000 description 3
- 241000724709 Hepatitis delta virus Species 0.000 description 3
- 101710085938 Matrix protein Proteins 0.000 description 3
- 101710127721 Membrane protein Proteins 0.000 description 3
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004460 liquid liquid chromatography Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 241000237505 Chlamys Species 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101710084021 Large envelope protein Proteins 0.000 description 2
- CBSOFSBFHDQRLV-UHFFFAOYSA-N N-methylbenzylamine hydrochloride Chemical compound [Cl-].C[NH2+]CC1=CC=CC=C1 CBSOFSBFHDQRLV-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960002233 benzalkonium bromide Drugs 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 208000037799 influenza C Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012434 mixed-mode chromatography Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- HXYCHJFUBNTKQR-RNFRBKRXSA-N (2R,3R)-heptane-1,2,3-triol Chemical compound CCCC[C@@H](O)[C@H](O)CO HXYCHJFUBNTKQR-RNFRBKRXSA-N 0.000 description 1
- SIDULKZCBGMXJL-UHFFFAOYSA-N 1-dimethylphosphoryldodecane Chemical compound CCCCCCCCCCCCP(C)(C)=O SIDULKZCBGMXJL-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UEYROBDNFIWNST-UHFFFAOYSA-N N-octadecanoylglycine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCC(O)=O UEYROBDNFIWNST-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000013622 capto Q Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- GSVLCKASFMVUSW-UHFFFAOYSA-N decyl(dimethyl)phosphine oxide Chemical compound CCCCCCCCCCP(C)(C)=O GSVLCKASFMVUSW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 description 1
- GCRLIVCNZWDCDE-SJXGUFTOSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]nonanamide Chemical compound CCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO GCRLIVCNZWDCDE-SJXGUFTOSA-N 0.000 description 1
- SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
- UPHWVVKYDQHTCF-UHFFFAOYSA-N octadecylazanium;acetate Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCCN UPHWVVKYDQHTCF-UHFFFAOYSA-N 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000012776 robust process Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11174660 | 2011-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201311896A true TW201311896A (zh) | 2013-03-16 |
Family
ID=45094875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101126141A TW201311896A (zh) | 2011-07-20 | 2012-07-19 | 製備病毒抗原及疫苗之方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2734619B1 (enExample) |
| JP (1) | JP6275641B2 (enExample) |
| KR (2) | KR20160096215A (enExample) |
| CN (1) | CN103827296B (enExample) |
| AU (1) | AU2012286098C1 (enExample) |
| BR (1) | BR112014001049A2 (enExample) |
| CA (1) | CA2841604C (enExample) |
| ES (1) | ES2653197T3 (enExample) |
| MX (1) | MX2014000753A (enExample) |
| RU (1) | RU2565827C2 (enExample) |
| TW (1) | TW201311896A (enExample) |
| WO (1) | WO2013010797A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524563A (zh) * | 2014-12-12 | 2015-04-22 | 普莱柯生物工程股份有限公司 | 疫苗组合物及其制备方法和应用 |
| EP3728287B1 (en) | 2017-12-19 | 2024-04-10 | CSL Behring Lengnau AG | Protein purification and virus inactivation with alkyl glycosides |
| JP7360594B2 (ja) * | 2017-12-28 | 2023-10-13 | 共立製薬株式会社 | ワクチン製剤、並びに魚類のイリドウイルス感染症予防方法 |
| US11690907B2 (en) | 2018-06-12 | 2023-07-04 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
| SG11202012366WA (en) | 2018-06-12 | 2021-01-28 | Kentucky Bioprocessing Inc | Virus and antigen purification and conjugation |
| US11529413B2 (en) | 2018-06-12 | 2022-12-20 | Kbio Holdings Limited | Virus and antigen purification and conjugation |
| US11696948B2 (en) | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
| CA3104392A1 (en) * | 2018-07-04 | 2020-01-09 | Probiogen Ag | Method for purifying an enveloped virus |
| PE20211140A1 (es) | 2018-11-15 | 2021-06-25 | Bayer Healthcare Llc | Metodos de inactivacion virica para la fabricacion continua de anticuerpos |
| RU2710239C1 (ru) * | 2019-06-14 | 2019-12-25 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства | Способ получения антигена или антигенов для производства противогриппозной вакцины и вакцина на его основе |
| EP4054630A2 (en) * | 2019-11-07 | 2022-09-14 | Seqirus UK Limited | Compositions and methods for producing a viral vaccine with reduced particle size |
| US20230212230A1 (en) * | 2020-04-29 | 2023-07-06 | Sk Bioscience Co., Ltd. | Influenza virus production method using single-use culture process system and rapid confirmation test of influenza virus antigen purification condition |
| KR102546626B1 (ko) * | 2020-04-29 | 2023-06-21 | 에스케이바이오사이언스(주) | 인플루엔자 바이러스 항원 정제 조건 신속 확인 시험 |
| CN112309502B (zh) * | 2020-10-14 | 2024-09-20 | 深圳市新合生物医疗科技有限公司 | 一种计算肿瘤新抗原负荷的方法及系统 |
| JP7898711B2 (ja) * | 2022-03-24 | 2026-08-03 | 国立大学法人 東京大学 | ウイルスの精製方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140762A (en) * | 1974-01-14 | 1979-02-20 | Sandoz Ltd. | Influenza sub-unit vaccine |
| US4240762A (en) * | 1979-03-12 | 1980-12-23 | Johnston Pump Company | Seal-aligning rigid coupling assembly |
| SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| CA2807534A1 (en) * | 2003-02-25 | 2005-02-17 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
| RU2283139C1 (ru) * | 2005-03-21 | 2006-09-10 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Способ получения антигенов для вакцины против вирусов гриппа |
| EP1982727A1 (en) * | 2007-04-17 | 2008-10-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for purification of viral proteins |
| JP5535910B2 (ja) * | 2007-08-28 | 2014-07-02 | バクスター・インターナショナル・インコーポレイテッド | ウイルスワクチンを生産する方法 |
| JP5518041B2 (ja) * | 2008-03-18 | 2014-06-11 | ノバルティス アーゲー | インフルエンザウイルスワクチン抗原の調製における改良 |
| KR20110074563A (ko) * | 2008-09-24 | 2011-06-30 | 메디뮨 엘엘씨 | 바이러스의 정제 방법 |
| CN102216450B (zh) * | 2008-09-24 | 2014-05-14 | 米迪缪尼有限公司 | 培养细胞、增殖和纯化病毒的方法 |
| GB0918830D0 (en) * | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
-
2012
- 2012-07-04 BR BR112014001049A patent/BR112014001049A2/pt not_active IP Right Cessation
- 2012-07-04 KR KR1020167020663A patent/KR20160096215A/ko not_active Withdrawn
- 2012-07-04 WO PCT/EP2012/063045 patent/WO2013010797A1/en not_active Ceased
- 2012-07-04 CA CA2841604A patent/CA2841604C/en not_active Expired - Fee Related
- 2012-07-04 CN CN201280035724.9A patent/CN103827296B/zh not_active Expired - Fee Related
- 2012-07-04 MX MX2014000753A patent/MX2014000753A/es not_active Application Discontinuation
- 2012-07-04 RU RU2014101484/10A patent/RU2565827C2/ru not_active IP Right Cessation
- 2012-07-04 AU AU2012286098A patent/AU2012286098C1/en not_active Ceased
- 2012-07-04 JP JP2014520591A patent/JP6275641B2/ja not_active Expired - Fee Related
- 2012-07-04 ES ES12734892.8T patent/ES2653197T3/es active Active
- 2012-07-04 KR KR1020147001348A patent/KR20140038530A/ko not_active Ceased
- 2012-07-04 EP EP12734892.8A patent/EP2734619B1/en active Active
- 2012-07-19 TW TW101126141A patent/TW201311896A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012286098A1 (en) | 2014-01-23 |
| CN103827296B (zh) | 2016-11-16 |
| KR20160096215A (ko) | 2016-08-12 |
| CA2841604C (en) | 2020-01-21 |
| RU2014101484A (ru) | 2015-07-27 |
| WO2013010797A1 (en) | 2013-01-24 |
| KR20140038530A (ko) | 2014-03-28 |
| MX2014000753A (es) | 2014-05-07 |
| JP2014524747A (ja) | 2014-09-25 |
| ES2653197T3 (es) | 2018-02-06 |
| JP6275641B2 (ja) | 2018-02-07 |
| CA2841604A1 (en) | 2013-01-24 |
| RU2565827C2 (ru) | 2015-10-20 |
| CN103827296A (zh) | 2014-05-28 |
| EP2734619B1 (en) | 2017-09-06 |
| EP2734619A1 (en) | 2014-05-28 |
| BR112014001049A2 (pt) | 2017-02-21 |
| AU2012286098C1 (en) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6275641B2 (ja) | ウイルス抗原およびワクチンの製造方法 | |
| AU2012286098B2 (en) | Process for producing viral antigen and vaccines | |
| EP0870508B1 (en) | Influenza vaccine | |
| CN107567496B (zh) | 有关病毒的无菌纯化方法 | |
| JP6385559B2 (ja) | 細胞培養体からのポリオウイルスの精製プロセス | |
| JP2012507272A (ja) | 新規な方法 | |
| US20220267738A1 (en) | Method For Purifying An Enveloped Virus | |
| AU2004249802B2 (en) | Improvements in virus production | |
| CN105473712B (zh) | 在细胞培养物中大规模生产病毒 | |
| JP7779858B2 (ja) | 使い捨て培養工程システムを用いたインフルエンザウイルス生産方法及びインフルエンザウイルス抗原精製条件の迅速確認試験 | |
| KR101581228B1 (ko) | 바이러스의 증식을 위한 ２-단계 온도 프로파일 | |
| KR101862332B1 (ko) | 인플루엔자 전바이러스 백신 제조 방법 | |
| HK1194763A (en) | Process for producing viral antigen and vaccines | |
| Weigel | Development of chromatography-based purification processes for cell culture-derived influenza virus particles | |
| US20230220356A1 (en) | Compositions and methods for producing a viral vaccine with reduced particle size | |
| KR102444684B1 (ko) | 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법 | |
| KR20210133732A (ko) | 인플루엔자 바이러스 항원 정제 조건 신속 확인 시험 | |
| CN1717480A (zh) | 病毒生产的改进 | |
| AU2007221746A1 (en) | Improvements in virus production |